Improving Access to New Diabetes Medications for All Patients
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes
This project aims to help more people with diabetes, especially those facing social challenges, get the most benefit from newer, life-improving glucose-lowering medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Florida NIH-funded |
| Lab location | 1 site (Gainesville, United States) |
| Project ID | NIH-11124763 on NIH RePORTER |
What this research studies
Many new diabetes medications offer significant heart and kidney benefits, but not everyone has equal access to them. This project looks at how social factors like income and education create barriers, leading to unequal health outcomes for people with type 2 diabetes. We are working to identify which patients would benefit most from these newer drugs and to develop strategies that ensure fair access for all. The goal is to improve the quality of diabetes care and reduce health disparities across the country.
Who could benefit from this research
Good fit: This project focuses on American adults living with type 2 diabetes, particularly those who may face social or economic barriers to accessing newer glucose-lowering drugs.
Not a fit: Patients who already have good access to and are benefiting from newer glucose-lowering drugs may not directly receive additional benefit from this specific project.
Why it matters
Potential benefit: If successful, this work could lead to better access to effective diabetes medications for all patients, potentially improving heart and kidney health outcomes and reducing health disparities.
How similar studies have performed: Previous studies have shown that improving care for high-benefit patient groups can also improve equity, as disadvantaged groups often have the largest gaps in care.
Where this research is happening
Gainesville, United States
- University of Florida — Gainesville, United States (Active)
Researchers
- Principal investigator: Guo, Jingchuan — University of Florida
- Study coordinator: Guo, Jingchuan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.